HER2-Positive Breast Cancers No Longer Brings a Poor Prognosis

HER2-Positive Breast Cancers No Longer Brings a Poor Prognosis
share Share

Brazilian researchers (Porto Alegre, RS, Brazil) recently examined whether HER2-positive breast cancers should still be associated with poor prognosis given the advance in HER2-targeted therapies.

 

HER2, found on the surface of all breast cells, is a protein involved in cell growth. HER2-positive breast cancers are normally aggressive and associated with poor outcomes. In these cases, HER2 are overly sensitive and excessively driven by growth factors. HER2-target therapies typically interfere with HER2 function to interrupt HER2-mediated cell growth.

 

  


Given that these therapies have become more common over recent years, a population-based study was conducted for5,121 HER2-positive breast cancer patients before and after the availability of HER2-targeted therapies. HER2-positive tumours were more likely to be lymph node-positive and high grade. Before the availability of HER2-targeted agents, patients with HER2 positive breast cancers had worse five-year survival than hormone receptor-positive patients (63.4% vs. 83.0%). In comparison, following the entry of HER2-targeted agents in clinical practice, five-year survival no longer differed (88.3% vs 90.4%).

 

The study authors conclude that ‘HER2 amplification is no longer a marker of poor prognosis for patients newly diagnosed with breast cancer’, but also caution that further analysis is needed to determine whether patients with HER2-enriched tumours that are clinically HER2-negative may benefit from HER2-targeted therapies.


Click here for the latest Women's Health news 

 

Image Credit: iStock


Source: Clinical Breast Cancer

«« Hologic Opens New Innovation Center in France


An AI Algorithm for Determining Breast Density on BI-RADS Scale »»

References:

Marczyk VR et al. (2022) Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence from A Population-Based Study. Clinical Breast Cancer.


Published on : Thu, 24 Mar 2022



Related Articles

Innovation Center in Aix-en-Provence, France (Photo: Business Wire) --The state-of-the-art facility in Aix-en-Provence... Read more

Researchers from the Cancer Registry of Norway demonstrated that a commercial artificial intelligence (AI) system could detect... Read more

Sexually Transmitted Disease (STD) Awareness Week is observed in the U.S. yearly during the second whole week of April. The U.S.... Read more

HER2, breast cancers Brazilian researchers (Porto Alegre, RS, Brazil) recently examined whether HER2-positive breast cancers should still be associated with poor prognosis given the advance in HER2-targeted therapies.

No comment


Please login to leave a comment...

Highlighted Products